BeiGene

Recent news

• Company notice
  Record of Investor Relations Activities of BeiGene, Ltd. (August 2026)
  SZSI · 2026/8/7
• Rating change
  RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450
  Market Newswire · 2026/8/25
• Rating change
  J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $425
  Market Newswire · 2026/7/23
• Rating change
  Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $415
  Market Newswire · 2026/9/10
• Rating change
  Barclays Maintains BeiGene(ONC.US) With Buy Rating, Cuts Target Price to $403
  Market Newswire · 2026/7/14
• Goldman Sachs: BeiGene (ONC.US) Q2 Sales Slightly Beat Expectations; Maintains "Buy" Rating
  AASTOCKS · 2026/8/24
• UBS Group: Most Chinese biotech firms exceeded sales expectations in the first half; global R&D catalysts will be key in the second half. Top pick: BeiGene (ONC.US)
  Zhitong Finance · 2026/9/7
• JPMorgan increased its holding in BeiGene (06160.HK) by 4.1197 million ordinary shares, valued at approximately HK$905 million.
  Market Newswire · 2026/8/14
• Rating change
  BeiGene (688235): Strong U.S. Market Performance and Efficient Advancement of Solid Tumor R&D
  China Post Securities · 2026/8/7
• Rating change
  Morgan Stanley Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $395
  Market Newswire · 2026/7/23
• Rating change
  BeiGene (688235): Strong sales of its flagship product and continued expansion of its pipeline.
  CITIC Securities · 2026/8/9
• Company notice
  BeiGene: U.S. Stock Market Announcement: Quarterly Report on Form 10-Q
  SZSI · 2026/8/6
• Rating change
  Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $370
  Market Newswire · 2026/8/10
• Rating change
  A Quick Look at Today's Ratings for BeiGene(ONC.US), With a Forecast Between $400 to $466
  Market Newswire · 2026/8/7
• Company notice
  BeiGene, Ltd. Investor Relations Activity Log – 20260806
  SZSI · 2026/8/7
• CLSA: Fundamentals of China's biotechnology sector remain solid; top picks are BeiGene (06160), Innovent Bio (01801), and WeLiShengBo (09887).
  Zhitong Finance · 2026/9/7
• Rating change
  BeiGene (688235): Profit growth to remain robust in Q2 2026; full-year revenue and profit guidance raised.
  Tianfeng Securities · 2026/8/28
• The Capital Group increased its holdings in BeiGene (06160.HK) by 1.9494 million H shares, valued at approximately USD 699 million.
  Market Newswire · 2026/9/28
• Company notice
  BeiGene: Announcement by BeiGene, Ltd. Regarding the Convening of the 2026 Semi-Annual Results Presentation
  SZSI · 2026/8/21
• Company notice
  BeiGene: Special Report on the Deposit and Actual Use of Funds Raised in the First Half of 2026 by BeiGene, Ltd.
  SZSI · 2026/8/27

Headlines are aggregated automatically and are not independently verified or edited by our team.